Compile Data Set for Download or QSAR
Report error Found 231 Enz. Inhib. hit(s) with all data for entry = 11153
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384427(US9932325, Example 122 | US9932325, Example 113 | ...)
Affinity DataIC50: 0.720nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384405(US9932325, Example 108 | US9932325, Example 104 | ...)
Affinity DataIC50: 0.960nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384428(US9932325, Example 115 | US9932325, Example 114 | ...)
Affinity DataIC50: 1.05nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US9932325, Example 144 | US9932325, Example 143 | ...)
Affinity DataIC50: 1.21nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384464(US9932325, Example 151 | US9932325, Example 150 | ...)
Affinity DataIC50: 1.22nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384485(US9932325, Example 172 | US9932325, Example 171 | ...)
Affinity DataIC50: 1.47nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384432(US9932325, Example 118 | US10590114, No. 118 | US1...)
Affinity DataIC50: 1.55nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384432(US9932325, Example 118 | US10590114, No. 118 | US1...)
Affinity DataIC50: 1.55nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384407(US9932325, Example 93 | US10590114, No. 93 | US111...)
Affinity DataIC50: 1.87nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384469(US9932325, Example 156 | US9932325, Example 155 | ...)
Affinity DataIC50: 1.95nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384382(US9932325, Example 69 | US9932325, Example 68 | US...)
Affinity DataIC50: 2.23nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384347(US9932325, Example 34 | BDBM384370 | US10590114, N...)
Affinity DataIC50: 2.31nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US9932325, Example 27 | US9932325, Example 26 | US...)
Affinity DataIC50: 3.41nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384392(US9932325, Example 78 | US10590114, No. 78 | US111...)
Affinity DataIC50: 3.69nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384455(US9932325, Example 141 | US10590114, No. 141 | US1...)
Affinity DataIC50: 3.94nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384310(US9932325, Example 218 | US9932325, Example 14 | U...)
Affinity DataIC50: 5.91nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384312(US9932325, Example 16 | US10590114, No. 16 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384311(US9932325, Example 15 | US10590114, No. 15 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384310(US9932325, Example 218 | US9932325, Example 14 | U...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384309(US9932325, Example 13 | US10590114, No. 13 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384318(US9932325, Example 20 | US10590114, No. 20 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384317(US9932325, Example 19 | US10590114, No. 19 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM196756(US9212173, 34 | US9932325, Example 18 | US10590114...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384314(US9932325, Example 17 | US10590114, No. 17 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US9932325, Example 23 | US9932325, Example 24 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US9932325, Example 23 | US9932325, Example 24 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384323(US9932325, Example 23 | US9932325, Example 24 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384321(US9932325, Example 21 | US10590114, No. 21 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384334(US9932325, Example 29 | US9932325, Example 28 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US9932325, Example 27 | US9932325, Example 26 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384330(US9932325, Example 27 | US9932325, Example 26 | US...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384328(US9932325, Example 25 | US10590114, No. 25 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM436212(US10590114, No. 4 | US11111235, No. 4 | US11591316...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM436211(US10590114, No. 3 | US11111235, No. 3 | US11591316...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384287(US9932325, Example 1 | US10590114, No. 1 | US11111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384299(US9932325, Example 8 | US10590114, No. 8 | US11111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384297(US9932325, Example 7 | US10590114, No. 7 | US11111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384294(US9932325, Example 5 | US10590114, No. 5 | US11111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384308(US9932325, Example 12 | US11591316, Compound 12)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384307(US9932325, Example 11 | US11591316, Compound 11)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM436217(US10590114, No. 9 | US11111235, No. 9 | US11591316...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384365(US9932325, Example 50 | US10590114, No. 50 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384355(BDBM384364 | US9932325, Example 38 | US10590114, N...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384363(BDBM384372 | US9932325, Example 46 | US10590114, N...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM50448118(CHEMBL3122113 | US9932325, Example 80 | US10590114...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384368(US9932325, Example 54B | US9932325, Example 54A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384366(US9932325, Example 52B | US9932325, Example 52A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384366(US9932325, Example 52B | US9932325, Example 52A | ...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM384373(US9932325, Example 60 | US10590114, No. 60 | US111...)
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/14/2023
Entry Details
US Patent

Displayed 1 to 50 (of 231 total ) | Next | Last >>
Jump to: